These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36426361)

  • 1. Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3-9-month intervals following two-dose inactivated vaccine (CoronaVac).
    Liao Y; Chen Y; Chen B; Liang Z; Hu X; Xing B; Yang J; Zheng Q; Hua Q; Yan C; Lv H
    Front Immunol; 2022; 13():1017590. PubMed ID: 36426361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older.
    Chen Y; Zhang X; Gong L; Liang Z; Hu X; Xing B; Liao Y; Yuan L; Chen G; Lv H
    Expert Rev Vaccines; 2023; 22(1):1079-1090. PubMed ID: 37877219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.
    Huang T; Hu Q; Zhou X; Yang H; Xia W; Cao F; Deng M; Teng X; Ding F; Zhong Z; Gao L; Sun J; Gong L
    BMC Infect Dis; 2024 Apr; 24(1):413. PubMed ID: 38641791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
    Tang R; Zheng H; Wang BS; Gou JB; Guo XL; Chen XQ; Chen Y; Wu SP; Zhong J; Pan HX; Zhu JH; Xu XY; Shi FJ; Li ZP; Liu JX; Zhang XY; Cui LB; Song ZZ; Hou LH; Zhu FC; Li JX;
    Lancet Respir Med; 2023 Jul; 11(7):613-623. PubMed ID: 36898400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
    Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W
    Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
    Li JX; Wu SP; Guo XL; Tang R; Huang BY; Chen XQ; Chen Y; Hou LH; Liu JX; Zhong J; Pan HX; Shi FJ; Xu XY; Li ZP; Zhang XY; Cui LB; Tan WJ; Chen W; Zhu FC;
    Lancet Respir Med; 2022 Aug; 10(8):739-748. PubMed ID: 35605625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Li J; Hou L; Guo X; Jin P; Wu S; Zhu J; Pan H; Wang X; Song Z; Wan J; Cui L; Li J; Chen Y; Wang X; Jin L; Liu J; Shi F; Xu X; Zhu T; Chen W; Zhu F
    Nat Med; 2022 Feb; 28(2):401-409. PubMed ID: 35087233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.
    Huang T; Zhang S; Dai DF; Wang BS; Zhuang L; Huang HT; Wang ZF; Zhao JS; Li QP; Wu SP; Wang X; Zhang WD; Zhao ZH; Li H; Zhang YP; Yang XL; Jiang XY; Gou JB; Hou LH; Gao LD; Feng ZC
    Lancet Respir Med; 2023 Aug; 11(8):698-708. PubMed ID: 37209700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
    Jin PF; Guo XL; Gou JB; Hou LH; Song ZZ; Zhu T; Pan HX; Zhu JH; Shi FJ; Du P; Huang HT; Liu JX; Zheng H; Wang X; Chen Y; Wan P; Wu SP; Wang XW; Xu XY; Yan FR; Li JX; Chen W; Zhu FC
    Lancet Reg Health West Pac; 2023 Jun; 38():100829. PubMed ID: 37360864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial.
    Liu X; Sun Z; Wang Z; Chen J; Wu Q; Zheng Y; Yang X; Mo L; Yan X; Li W; Zou Y; Song H; Qian F; Lu J; Zhou H; Wang Y; Xiang Z; Yu H; Lin J; Yuan L; Zheng Y
    EClinicalMedicine; 2023 Oct; 64():102231. PubMed ID: 37767190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, immunogenicity and protective effectiveness of heterologous boost with a recombinant COVID-19 vaccine (Sf9 cells) in adult recipients of inactivated vaccines.
    Luo W; Gan J; Luo Z; Li S; Wang Z; Wu J; Zhang H; Xian J; Cheng R; Tang X; Liu Y; Yang L; Mou Q; Zhang X; Chen Y; Wang W; Wang Y; Bai L; Wei X; Zhang R; Yang L; Chen Y; Yang L; Li Y; Liu D; Li W; Chen L
    Signal Transduct Target Ther; 2024 Feb; 9(1):41. PubMed ID: 38355676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
    Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.
    Jiang H; Jin P; Guo X; Zhu J; Wang X; Wan P; Wan J; Liu J; Li J; Zhu F
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
    Li JX; Hou LH; Gou JB; Yin ZD; Wu SP; Wang FZ; Zhang Z; Peng ZH; Zhu T; Shen HB; Chen W; Zhu FC;
    Lancet Infect Dis; 2023 Oct; 23(10):1143-1152. PubMed ID: 37352880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.
    Zhang H; Xu N; Xu Y; Qin P; Dai R; Xu B; Wang S; Ding L; Fu J; Zhang S; Hua Q; Liao Y; Yang J; Hu X; Jiang J; Lv H
    Nat Commun; 2023 Aug; 14(1):4757. PubMed ID: 37553338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.